Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

SurgiLight Begins Phase I Clinical Studies in Spain
Mar 2001
ORLANDO, Fla., March 9 -- SurgiLight Inc. announced that it would begin Human Phase I clinical studies using its IR-3000 laser for Laser Presbyopia Reversal (LPR) in Spain within a month. Presbyopia is a visual condition in which loss of elasticity of the lens of the eye causes defective accommodation and inability to focus sharply for near vision.
   The company has received Institutional Review Board (IRB) approval at the Department of Ophthalmology, Institute Universitari Dexus, where Carlos Verges will perform this Phase I clinical study on a total of ten eyes. This clinical study follows the initiation of the baseline studies and research at the University of Utah Health and Sciences Center, John A. Moran Eye Center. Nick Mamalis began the baseline study in February and the preliminary results from these studies have been promising, said SurgiLight.

News & Features

Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,
x We deliver – right to your inbox. Subscribe FREE to our newsletters.